SecBot SecBot
8-K ·Filed May 5, 2026

DMAAR

Drugs Made In America Acquisition Corp.
NEUTRAL
Impact 6/10
Horizonmonths Processed5mo ago SEC0001213900-26-052324
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor for the filing of the S-4 registration statement and subsequent redemption levels; the deal's success hinges on PAGC's ability to deliver verified revenue contracts meeting the valuation milestones. Watch for any PIPE financing announcements as a signal of institutional support.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

DMAA, a SPAC, entered into a definitive merger agreement with private AI/analytics company Power Analytics Global Corp (PAGC). The target enterprise valuation is $1.0 billion, subject to a milestone schedule based on PAGC's verified revenue contracts, with a floor of $300 million. Post-closing ownership is expected to be ~90% to former PAGC shareholders and ~10% to DMAA shareholders, prior to any PIPE dilution. The deal requires DMAA to have at least $15-30 million in cash at closing from its trust account and/or a PIPE financing.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Definitive merger agreement signed April 29, 2026 (amended April 30, 2026) for PAGC to merge into DMAA, with PAGC as the surviving public entity.
  • Target enterprise value of $1.0 billion, subject to valuation milestones tied to verified revenue contracts ($15M-$75M+ in contract value). Floor valuation of $300 million.
  • Expected post-closing ownership: ~90% to former PAGC shareholders, ~10% to DMAA shareholders (pre-PIPE dilution).
  • DMAA targets minimum cash at closing of $30 million (floor $15 million) from trust account and/or PIPE financing.
  • Closing conditions include DMAA shareholder approval, SEC effectiveness of Form S-4, Nasdaq listing, no MAE, PAGC debt-free, and delivery of IP schedule and GSA CAGE code.

Financial Impact

Not specified

Risk Factors

  • Failure to secure sufficient cash at closing (redemptions or PIPE shortfall) could jeopardize the transaction.
  • PAGC must validate revenue contracts to achieve the targeted $1B valuation; any shortfall would reduce the exchange ratio and potentially trigger renegotiation or termination.
  • Shareholder approval and regulatory clearance are required; any delays or opposition could extend timeline or kill the deal.

Market Snapshot

Exchange
Nasdaq
Sector
Blank Checks

Investment Themes

Traditional Finance

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-052324
Document: ea0289172-8k425_drugs.htm0001213900-26-052324
Document: ea028917201ex2-2.htm0001213900-26-052324
Document: ea028917201ex2-3.htm0001213900-26-052324
Document: 0001213900-26-052324-index-headers.html0001213900-26-052324
Document: 0001213900-26-052324-index.html0001213900-26-052324
Document: 0001213900-26-052324.txt0001213900-26-052324
3 reports for DMAAR
Performance horizon
Filters
Rows
Reports for DMAAR — sortable, filterable
TypeNow
May 5, 2026
25w ago
8-K
NEUTRAL ★ 6/10
—awaiting T+20——
May 1, 2026
25w ago
8-K
BEARISH ★ 7/10
—awaiting T+20——
Apr 8, 2026
28w ago
8-K
BULLISH ★ 7/10
—awaiting T+20——
Showing 3 of 3

US Market Status

Market Closed — Opens Thu (11h 51m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026